Track Zosano Pharma Corporation — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Zosano Pharma Corporation ZSAN · Stock Open Zosano Pharma Corporation in new tab

0.5576 USD
Loading chart...

DCF valuation

Model fair value for Zosano Pharma Corporation (ZSAN)
Result
Sign in to run the valuation for ZSAN.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

Zosano Pharma Corporation Logo Zosano Pharma Corporation Analysis (ZSAN)

United States Health Care Official Website Stock

Is Zosano Pharma Corporation a good investment? Zosano Pharma Corporation (ZSAN) is currently trading at 0.5576 USD.

Investor FAQ

Does Zosano Pharma Corporation pay a dividend?

No, it does not currently pay a dividend.

What asset class is Zosano Pharma Corporation?

Zosano Pharma Corporation is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

Company Profile

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. On June 1, 2022, Zosano Pharma Corporation filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Exchange Ticker
NMS (United States) ZSAN
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion